Company news

SAB Biotherapeutics, Inc. news in 2026

SAB Biotherapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

November 5, 2026

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08: 30 AM ET

October 29, 2026

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

October 14, 2026

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

October 13, 2026

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

October 1, 2026

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

September 22, 2026

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08: 30 AM ET

July 30, 2026

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 12, 2026

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08: 30 AM ET

May 5, 2026

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

April 22, 2026

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

April 14, 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 18, 2026

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

March 16, 2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 16, 2026

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

March 9, 2026

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

March 8, 2026

SAB BIO to Participate in Upcoming Investor Conferences

February 4, 2026

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

January 7, 2026

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Calls in 2026

Decks in 2026